WO1989012693A1 - Serotyping dna probes - Google Patents
Serotyping dna probes Download PDFInfo
- Publication number
- WO1989012693A1 WO1989012693A1 PCT/AU1989/000268 AU8900268W WO8912693A1 WO 1989012693 A1 WO1989012693 A1 WO 1989012693A1 AU 8900268 W AU8900268 W AU 8900268W WO 8912693 A1 WO8912693 A1 WO 8912693A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- enterobacteriaceae
- fragment
- antigen
- serotype
- Prior art date
Links
- 239000000523 sample Substances 0.000 title claims abstract description 60
- 239000012634 fragment Substances 0.000 claims abstract description 64
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 58
- 239000000427 antigen Substances 0.000 claims abstract description 57
- 241000588921 Enterobacteriaceae Species 0.000 claims abstract description 50
- 239000003298 DNA probe Substances 0.000 claims abstract description 45
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 43
- 108020003215 DNA Probes Proteins 0.000 claims abstract description 42
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 30
- 239000013612 plasmid Substances 0.000 claims description 65
- 241000588724 Escherichia coli Species 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 44
- 201000010099 disease Diseases 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 238000004458 analytical method Methods 0.000 claims description 26
- 229960005486 vaccine Drugs 0.000 claims description 25
- 230000001580 bacterial effect Effects 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 108091008146 restriction endonucleases Proteins 0.000 claims description 19
- 239000013599 cloning vector Substances 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 12
- 241000607142 Salmonella Species 0.000 claims description 10
- 230000029087 digestion Effects 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 6
- 230000000688 enterotoxigenic effect Effects 0.000 claims description 6
- 230000002285 radioactive effect Effects 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 208000037157 Azotemia Diseases 0.000 claims description 3
- 241000607768 Shigella Species 0.000 claims 4
- 108020004414 DNA Proteins 0.000 description 72
- 239000002158 endotoxin Substances 0.000 description 27
- 229920006008 lipopolysaccharide Polymers 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 18
- 238000009396 hybridization Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 239000000499 gel Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 6
- 102000004594 DNA Polymerase I Human genes 0.000 description 6
- 108010017826 DNA Polymerase I Proteins 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 6
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 208000002109 Argyria Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 108091008053 gene clusters Proteins 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000011544 gradient gel Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 229940016590 sarkosyl Drugs 0.000 description 3
- 108700004121 sarkosyl Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AAXCQFOXUJMCCW-PETQGJDISA-N LPS core Chemical compound O([C@H]1[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]([C@@H](CO[C@]2(O[C@@H]([C@@H](OC3[C@H]([C@@H](OC4[C@H]([C@@H](OC5[C@@H]([C@@H](O[C@@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O6)OC6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O6)O)O5)O)[C@H](O)[C@@H]([C@@H](O)COC5[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O5)O)O4)O)[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)O3)O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](O[C@]4(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C4)[C@@H](O)CO)C(O)=O)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)O1)OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C[C@H]1O[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]1O AAXCQFOXUJMCCW-PETQGJDISA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 239000008051 TBE buffer Substances 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000011509 clonal analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000702005 Bacillus phage SPP1 Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 239000004374 Basic methacrylate copolymer Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001237659 Mazia Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 239000004400 Neutral Methacrylate Copolymer Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 241000392514 Salmonella enterica subsp. enterica serovar Dublin Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241000602423 Vibrio cholerae O1 Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007478 blood agar base Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 101150098466 rpsL gene Proteins 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to the identification and isolation of DNA fragments which may be utilised inter alia as DNA probes and in live vaccine carrier strains.
- the outer membrane of the cell wall of Gram negative bacteria comprises proteins, phospholipids and lipopolysaccharide (LPS) and of these the LPS is by far the most abundant molecule on the cell surface.
- the LPS is composed of three regions: the innermost is the lipid-A moiety which forms the outer leaflet of the lipid bilayer of the outer membrane; the central region is the core oligosaccharide, and outermost is the O-antigen side-chain consisting of a series of repeat units usually of specific sugars. The sequence and types of sugars and their linkages is what determines the O-serotype of the bacterium.
- the diagnosis of disease requires the specific identification of the aetiological agent and this usually involves isolation of the organism on selective media and then subjecting it to a battery of biochemical tests which can take days before a positive identification can be made. It may then be necessary to serotype the organism especially if the epidemiology of the disease is to be examined. Serotyping can usually only proceed after the type of organism has been determined, and again is time consuming. Thus, a more rapid means of both diagnosis and serotyping would be of considerable benefit especially since many of the Enterobacteriaceae can cause life-threatening disease and are in fact the major causes of infant mortality in developing countries such as India, Bangladesh and much of South America. It is accordingly an object of the present invention _ _ .
- a DNA probe including a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae. which probe detects the presence of the rfb region of an Enterobacteriaceae.
- the fragment of DNA contains genes encoding for the synthesis of the O-antigen of the 0101, 0157 or 02 serotype of an Escherichia coli.
- the Escherichia coli is an Enterotoxigenic E.coli (ETEC) .
- a DNA probe kit including a first DNA probe including a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae, which probe detects the presence of the rfb region of an Enterobacteriaceae; and a second DNA probe including a fragment of DNA which detects the presence of the rfb region of an Enterobacteriaceae in a manner different to said first probe such that the first and second probes are serotype specific.
- the genes responsible for the production of the O-antigen of the lipopolysaccharide of members of the Enterobacteriaceae are encoded within the gene cluster referred to as the rfb locus.
- the structure of the O-antigen also varies.
- the serotype of the bacterium is different.
- this region of the bacterial chromosome represents a set of genes which are directly related to the serotype of the organism, and thus variation in this region is absolutely related to the change in the serotype.
- the DNA probes according to the present invention make it possible to directly analyse the variation at rfb and correlate this with the serotype and thus provide a rapid means of serotyping an organism, as well as being able to differentiate one species from another.
- a DNA probe including a plasmid cloning vector; and a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae inserted into a suitable site in the plasmid cloning vector.
- the fragment of DNA may include the entire rfb locus of the Enterobacteriaceae or a fragment thereof.
- the Enterobacteriaceae may be an E.coli of the 01, 0157 or 02 serotype.
- Enterobacteriaceae is an E.coli of the 0101 serotype
- a fragment having a minimum length of approximately 8.9 Kb and a maximum length of approximately 11.8 Kb is required for 0101 0-antigen biosynthesis when it is introduced into E.coli K-12.
- the plasmid cloning vector may be of any suitable type.
- the plasmid cloning vector ⁇ HC79 has been found to be suitable.
- the fragment of DNA may be inserted into the BamHI site on the plasmid pHC79.
- the plasmid so formed has been designated pPM 1301. By deleting rfb DNA a derivative pPM 1305 has been derived.
- a DNA probe including the plasmid pPM 1305 or a digestion derivative thereof.
- Fragments of the clone pPM 1305 may be produced by partial digestion as described below. At present six fragments of pPM 1305 have been envisaged. These are designated plasmids pPM 1321, pPM 1322, pPM 1323, pPM 1324, pPM 1325, pPM 1326, pPM 1330 and pPM 2218. Samples of the plasmids are maintained in the Culture Collection of the Universith of Sydney, North Terrace, Sydney, South Australia. These are illustrated in Figure 6 below.
- a DNA probe including a plasmid from which rfb DNA has been deleted and selected from plasmids pPM 1305, pPM 1322, pPM 1323, pPM 1324, pPM 1325, pPM 1326, pPM 1330 and pPM 2218 and mixtures thereof.
- the plasmids pPA1343, pPA1344 and pPA1345 are examples of clones containing the 02 rfb region. Accordingly in a preferred form, there is provided a DNA probe including a plasmid selected from plasmids pPA1343, 1344 or 1345 or a digestion derivative thereof. This has great potential in the development of vaccines against diseases caused by Enteobacteriaceae where the O-antigen is a protective antigen, that is, where the protection is serotype specific. These clones also provide a basis for developing further probes. Similarly this approach has also been used to clone the genes for the 0157 rfb region. Plasmid pPM1354 represents an example of such a clone.
- a DNA probe including a plasmid pPM1354, or a digestion derivative thereof. This clone has potential for both vaccine development and for specific probes.
- E.coli of the 0157 serotype are responsible for haemorrhatic uraemic syndrome and are referred to as
- E.coli Enterohaemorratic E.coli and EHEC. This is a severe condition and can often lead to death, and vaccines against this disease are not presently available.
- the advantages of such probes include: the presence of rfb and closely linked DNA can be detected even in the absence of gene expression, a problem which may arise if the O-antigen is incompatible with the core region of the recipient organism, or if the recipient is expressing its own O-antigen and effectively out-competing the O-antigen encoded by the cloned DNA; the identification of an rfb clone is greatly simplified; a restriction map of the region to be cloned can be determined beforehand by Southern DNA hybridization, and this could permit a better choice of restriction enzyme for cleaving the chromosomal DNA prior to cloning.
- the probes enabled us to differentiate two 0115 strains, one which was an enterotoxigenic E.coli (ETEC) and another which was associated with septicaemia.
- ETEC enterotoxigenic E.coli
- these results illustrate that the probes may also enable us to differentiate organisms which are apparently of the same serotype but produce different diseases. This is extremely important because of course some E.coli serotypes are part of natural human bacterial flora.
- the DNA probes according to the present invention may be labelled in any suitable manner.
- a radioactive or non-radioactive label may be used.
- radioactive isotopes of phosphorus or sulphur e.g. 32 phosphorus and 35 sulphur may be used.
- non-radioactive labelling is preferred, a biotinylated photo-sensitive label may be selected.
- a method for preparing a DNA probe which method includes providing a plasmid cloning vector; a first restriction enzyme; and a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae; partially digesting the plasmid cloning vector with the restriction enzyme; and inserting the fragment of DNA into a restriction site.
- the restriction site chosen may correspond to the restriction enzyme used or be compatible therewith.
- the plasmid cloning vector may be of any suitable type* Tne plasmid cloning vector pHC79 has been found to be suitable. Since this plasmid cloning vector includes a BamHI restriction site, a corresponding BamHI or Sau 3A restriction enzyme is preferred.
- the ligated DNA so formed may be packaged in vitro and transduced into a suitable bacterial strain.
- an E.coli strain may be used.
- An E.coli K-12 strain may be used.
- the E.coli K-12 strain DH1 has been found to be suitable.
- the method of preparing a DNA probe may further include providing a plurality of restriction enzymes; and digesting the ligated DNA with the restriction enzymes to produce restriction fragments of differing size.
- the restriction enzymes may include Mlul, Kpn 1,
- the fragments may be subjected to the further step of filling the protruding ends so formed. This may be undertaken utilizing the Klenow fragment of DNA polymerase 1.
- the sub clones so formed may include the plasmids pPM 1321, pPM 1322, pPM 1323, pPM 1324, pPM 1325, pPM 1326, pPM 1330 and pPM 2218.
- the plasmids pPM 1321, pPM 1330 and pPM 1326 are preferred as they have been found to be highly conserved. It is hypothesized that the plasmids encode part of the region that specifies the OlOl serotype and may be associated with any common properties of the O-antigen chains that allow ETEC to be more efficient pathogens or inhabitants of the intestinal tract are likely to be found encoded in this region of the rfb cluster.
- a method of diagnosing a disease which method includes providing a sample to be tested; and at least one DNA probe including a fragment of DNA which probe detects the presence of the rfb region of an Enterobacteriaceae; contacting the sample with the at least one DNA probe; and _ _
- the method of diagnosis may in addition provide a method of serotyping the organism responsible for the disease.
- the method of diagnosis may include providing a series of samples to be tested; and a DNA probe kit including a first DNA probe including a fragment of DNA which detects the presence of the rfb region of an Enterobacteriaceae: and a second DNA probe including a fragment of
- DNA which detects the presence of the rfb region of an Enterobacteriaceae in a manner different to said first probe such that the first and second probes are serotype specific; contacting each sample with a different DNA probe from the kit; and subjecting the products thereof to a series of assays.
- the one such sample to be tested may be of any suitable type.
- a faecal sample may be used.
- the or each DNA probe is preferably a radioactively or non-radioactively labelled DNA probe, as described above.
- the product may be assayed in any suitable manner.
- a Western and/or color blot analysis may be used.
- the plasmids including restriction fragments of DNA including substantially the whole of the rfb locus of an
- Enterobacteriacae for example plasmid pPM 1305 may be inserted into a suitable avirulent bacterial carrier strain which may in turn function as a live vaccine.
- a suitable avirulent bacterial carrier strain which may in turn function as a live vaccine.
- a method of preparing an avirulent strain of an enterobacterium which method includes providing a sample of a preselected bacterial strain; and a plasmid including a fragment of DNA containing genes encoding for the synthesis of the
- the plasmid may be plasmid pPM 1305.
- the preselected bacterial strain may be selected from Salmonella and Shiqella strains. Salmonella tvphimurium. Salmonella typhi and Salmonella dublin have been found to be suitable.
- Diseases of interest may include those generated by any enterobacterial strain.
- the avirulent strain of an enterobacterium referred may provide the basis for a vaccine composition.
- the vaccine composition may be used as a live oral vaccine against enteropathogenic diseases of man or domestic animals.
- the genes for group- (rfb) and type-antigen biosynthesis of Shiqella flexneri may be introduced into the preselected strain. Further changes may include introduction of the Shi ⁇ ella LPS core biosynthesis genes (rfa) so that the strain expresses the O-antigen of the appropriate Shiqella specificity on the cell surface. Analysis of the LPS by silver staining, ELISA and haemagglutination inhibition may be used to assay the production of the O-antigen. Immunogenicity may be assessed in mice, and rabbits and ultimately monkeys.
- a vaccine composition useful for effecting immunity against diseases of an Enterobacteriaceae including a bacterial carrier strain; and a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae, inserted into the chromosome of the bacterial carrier strain.
- the bacterial carrier strain may be selected from Salmonella and Shiqella strains.
- the Enterobacteriaceae is preferably an E.coli of the 0101 serotype and the fragment of DNA has a munimum length of approximately 8.9 kilobase pairs, and a maximum length of approximately 11.8 kilobase pairs.
- the Enterobacteriaceae is an E.coli of the 0157 or 02 serotype.
- the vaccine composition may be provided in any suitable form.
- the vaccine composition may be provided in an oral or injectable form.
- Suitable carriers including aqueous and/or alcoholic carriers may be included.
- a buffered saline solution may be used.
- Other recipients and compounding ingredients known per se in the art may be included if desired.
- a method for the prophylactic treatment of diseases of an Enterobacteriaceae in mammals which method includes providing a mammal to be treated; and a vaccine composition useful for effecting immunity against diseases of an Enterobacteriaceae. including 0 a bacterial carrier strain; and a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an
- Enterobacteriaceae inserted into the chromosome of the bacterial carrier strain; and 5 administering to the mammal a prophylactically effective amount of the vaccine composition.
- a method for the prophylactic treatment of diseases of E.coli of the 0157 serotype in o mammals, including humans which method includes providing a mammal to be treated; and a vaccine composition including a Salmonalla or Shiqella carrier strain; and/or a fragment of DNA derived from plasmid pPM1354, or a digestion derivative thereof; and administering to the mammal a prophylatically effective amount of the vaccine composition.
- Q E.coli of the 0157 serotype are responsible for haemorrhatic uraemic syndrome and are referred to as Enterohae orratic E.coli and EHEC.
- Plasmid DNA of single and double digests were analysed in 0.8% and 1.0% agarose gels in TBE buffer. The lines indicate the extent of cloned DNA retained in each of the derivatives of pPM1305. Their ability to mediate synthesis of 0101 O-antigen is indicated.
- pPM 1305 was initially digested with Mlul and insert DNA ligated into the Mlul sites of pLG339 (Stoker et al. 1982) forming pPM1330.
- E.coli was digested with restriction endonucleases PstI,
- the two subclones pPM1321 and pPM1326 from the 0101 rfb clone pPM1305 are believed to represent a highly conserved region of DNA within the rfb gene cluster. These subclones were used as radio-labelled probes to detect restriction fragment length polymorphisms (RFlPs) within 018 and 02 E.coli.
- RlPs restriction fragment length polymorphisms
- the restriction maps obtained (D) from using these probes in Southern hybridisation analysis (A, B, C) show the high degree of relatedness between 018 and others not shown on E.coli and the probable close evolutionary relationships.
- the hybridizations were performed at high stringency; 0.2 x SS C at 65°C.
- the autoradiography was exposed for 2 days at - 70°C using intensifying screens.
- Competent cells (0.2ml) were mixed with 1 ug DNA, incubated on ice for 30 min, then heat shocked (42°C) for 2 min. The cells were then allowed to express in nutrient broth for 60 min. at 37°C with shaking and the mixture plated onto the appropriate antibiotic plate.
- Molecular cloning Molecular cloning
- genomic DNA from B41 a cosmid library was constructed as previously described (14) .
- 1-2 ug of genomic DNA partially digested with Sau3A was cloned into the BamHI site of 6 ug alkaline phosphatase treated BamHI digested pHC79 DNA.
- the ligated DNA was packaged in vitro and transducted into E.coli K-12 strain DHL This procedure usually yielded 1000-2000 ampicillin resistant colonies.
- Plasmids were transformed into the minicell producing stran DS410. Minicells were purified on sucrose gradients and the plasmid encoded proteins were labelled with -x c t S3-methionine and solubilized in sample buffer as previously described (13) . After electrophoresis in SDS on 11-20% polyacrylamide gels, the dried gel was subjected to autoradiography using Kodak X-omat film at room temperature. Restriction analysis
- Protuding ends created by cleavage with BamHI and SacI were filled or removed using the Klenow fragment of DNA polymerase I.
- Klenow fragment Typically, 1.6ug of digested DNA, 2 ul of each dNTP (2mM) and 5 units of Klenow fragment (Pharmacia) were mixed and left at room temperature for 30 min. The reaction was stopped by the addition of lul of -.5mM EDIA and incubation at 65°C for 15 min. Unincorporated dNTPs and enzyme were removed by centrifugation through a Sepharose C1-6B column.
- Colloidal gold particles (c. 15-20nm) were prepared using the citrate method as described (de Mey and Meormans, 1986) and conjugated with Protein A (Pharmacia) . Immunoqold labelling of whole cells
- Plasmid DNA was Nick translated with DNA Polymerase i and Southern DNA hybridization analysis (Southern, 1975) was carried out according to a modification of Maniatis et.al. (1982). [ 32 p3 labelled DNA of pPM1305 and its subclones were used to probe suitably digested genomic DNA from a number of 0101 isolates. Autoradiography was carried out at -70°C on Kodak X-omat film, with intensifying screens. The exposure time was 3 days.
- the cosmid pPM1301 was reduced in size in a two stage process: a partial Hindlll digestion to produce
- the coding region of the 0101 rfb gene cluster must extend from the region defined by the Sall-Hpal restriction endonuclease sites at (6.0-7.3kb) to the region o between the Sacl-Mlul sites (at 16.2-17.8 kb) ; i.e. a minimum of 8.9 kb and a maximum of 11.8 kb of DNA is required for
- E.coli isolates tested regardless of the O-serotype. There was no hybridization with eithr V.cholerae, Salmonella or the E.coli K-12 rfb delete strain, QE35 (Sunshine and Kelly, 1971) . Interestingly, this probe reacts strongly with several apparently immunologically unrelated serotypes and the basis for this is being examined.
- Figure 6 shows that when pPM1322 is used as a probe under conditions of high stringency, this fragment appears to be highly conserved among all isolates.
- the strain H510a which has a unique LPS banding pattern, while hybridizing with sequences on pPM1322 exhibits a markedly different pattern of fragments, not surpisingly there is no detectable homology with the rfb delete strain Q35 or the E.coli K-12 host strain DHL
- Figure 7 shows that when pPM1324 is used as a probe under the same conditions as pPM1322, H510a exhibits a unique pattern, whereas 8CE275/6, VAC1676 and VC17651 exhibit identical patterns.
- Strains B41 and KAT11706 have a fragment in common with the other isolates (except H510a) . No hybridization is seen with strains Q35 or DHl. Interestingly, this probe fails to detect an identical fragment in B41, suggesting that all of the cloned DNA in ⁇ PM1323 and pPM1324 is not contiguous, probably due to the deletion process by which they were generated. Discussion
- At least six proteins are encoded within the minimal coding region, implicating them in the synthesis and assembly of the O-subunit.
- Production of the 0101 O-antigen as LPS in an rfb delete strain QE35 implies that only the rfb genes carried by the clones are necessary for its expression and assembly on the E.coli K-12 core (data not shown). Since both structure of 0101 LPS is unknown, and the precise minimal coding region is not defined, it is not possible to say whether all of the proteins expressed in minicells or other additional undetected proteins are required for the synthesis of 0101 O-antigen. Subcloning and deletion analysis suggests that the predicted 9kb required for the _ _
- 0101 isolates that we have examined appear to exhibit some variability in the LPS, as judged by SDS-PAGE. This difference is not detected serologically with polyvalent antiserum. There are no reports in the literature of 0101 serotype variants, despite the fact that it is a common animal ETEC serotype. It is not yet possible to speculate on the chemical relationships between the different 0101 patterns. The genetic relatedness, as judged by DNA hybridization, one may predict that these differences may simply reflect minor modifications in the O-chain. Current data suggest that multiple 0101 LPS types exist: one type defined by H510a and other types observed in B41, KATH706, 8CE275/6, VAC1676 and VC1751.
- the DNA hybridization data suggest that the enzymes involved in H510a LPS biosynthesis are less closely related to the other types which share common restriction fragments.
- the distinct LPS pattern on SDS-PAGE of B41 may reflect the sequence of gene duplication that we have observed in this strain, since the clones of the rfb region of B41, i.e. DHl(pPM1305) and DHl(pPM1330) more closely resemble the LPS patterns of the other 0101 isolates.
- the 0101 serotype and may be useful in determining the relationships between strains of serotypes other than 0101. Since these probes can hybridize to serologically unrelated serotypes (data not shown; Beger et al. , 1988), they may also form the basis for developing rapi diagnostic probes capable of differentiating disease-causing organisms from the commensal flora of the same serotype. Conventional serotyping has not provided a means of identifying disease-causing organisms. The detection of O-serotype variants by DNA hybridization analysis may provide a more specific method for identifying pathogenic organisms.
- rfb 0101 genes also provides a basis for the construction of a hybrid vaccine strain in avirulent Salmonella (Stevenson and Manning, 1985), since it has been documented that antibodies to 0101 are more hghly protective against 010LK99/F41 challenge than antibodies to the colonization factors or adhesins K99 or F41 (Duchet-Suchaux, 1986).
- SPP1 the arrangement of restriction endonuclease generated fragments. Mol. Gen. Genet. 168 : 165-172.
Abstract
A DNA probe including a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae, which probe detects the presence of the rfb region of an Enterobacteriaceae.
Description
SKROTY ING DNA PROBES The present invention relates to the identification and isolation of DNA fragments which may be utilised inter alia as DNA probes and in live vaccine carrier strains. The outer membrane of the cell wall of Gram negative bacteria comprises proteins, phospholipids and lipopolysaccharide (LPS) and of these the LPS is by far the most abundant molecule on the cell surface. The LPS is composed of three regions: the innermost is the lipid-A moiety which forms the outer leaflet of the lipid bilayer of the outer membrane; the central region is the core oligosaccharide, and outermost is the O-antigen side-chain consisting of a series of repeat units usually of specific sugars. The sequence and types of sugars and their linkages is what determines the O-serotype of the bacterium.
The diagnosis of disease requires the specific identification of the aetiological agent and this usually involves isolation of the organism on selective media and then subjecting it to a battery of biochemical tests which can take days before a positive identification can be made. It may then be necessary to serotype the organism especially if the epidemiology of the disease is to be examined. Serotyping can usually only proceed after the type of organism has been determined, and again is time consuming. Thus, a more rapid means of both diagnosis and serotyping would be of considerable benefit especially since many of the Enterobacteriaceae can cause life-threatening disease and are in fact the major causes of infant mortality in developing countries such as India, Bangladesh and much of South America. It is accordingly an object of the present invention
_ _ .
to overcome, or at least alleviate, one or more of the difficulties related to the prior art.
Accordingly, in a first aspect, there is provided a DNA probe including a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae. which probe detects the presence of the rfb region of an Enterobacteriaceae.
More preferably the fragment of DNA contains genes encoding for the synthesis of the O-antigen of the 0101, 0157 or 02 serotype of an Escherichia coli. Preferably the Escherichia coli is an Enterotoxigenic E.coli (ETEC) .
In a preferred aspect of the present invention there is provided a DNA probe kit including a first DNA probe including a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae, which probe detects the presence of the rfb region of an Enterobacteriaceae; and a second DNA probe including a fragment of DNA which detects the presence of the rfb region of an Enterobacteriaceae in a manner different to said first probe such that the first and second probes are serotype specific.
Most of the genes responsible for the production of the O-antigen of the lipopolysaccharide of members of the Enterobacteriaceae are encoded within the gene cluster referred to as the rfb locus. There is variation at this locus and as a result the structure of the O-antigen also varies. The direct consequence of this is that the serotype of the bacterium is different. Thus this region of the bacterial chromosome represents a set of genes which are
directly related to the serotype of the organism, and thus variation in this region is absolutely related to the change in the serotype. Thus, the DNA probes according to the present invention make it possible to directly analyse the variation at rfb and correlate this with the serotype and thus provide a rapid means of serotyping an organism, as well as being able to differentiate one species from another.
In a still further aspect of the present invention there is provided a DNA probe including a plasmid cloning vector; and a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae inserted into a suitable site in the plasmid cloning vector. The fragment of DNA may include the entire rfb locus of the Enterobacteriaceae or a fragment thereof. The Enterobacteriaceae may be an E.coli of the 01, 0157 or 02 serotype. Where the Enterobacteriaceae is an E.coli of the 0101 serotype, we have found that a fragment having a minimum length of approximately 8.9 Kb and a maximum length of approximately 11.8 Kb is required for 0101 0-antigen biosynthesis when it is introduced into E.coli K-12.
The plasmid cloning vector may be of any suitable type. The plasmid cloning vector ρHC79 has been found to be suitable. The fragment of DNA may be inserted into the BamHI site on the plasmid pHC79. The plasmid so formed has been designated pPM 1301. By deleting rfb DNA a derivative pPM 1305 has been derived.
Accordingly, in a preferred form there is provided a DNA probe including the plasmid pPM 1305 or a digestion
derivative thereof.
Mini cell analysis of proteins produced by the plasmid clone pPM 1305 have demonstrated that O-antigen synthesis is genetically complex with at least 6 proteins involved.
Fragments of the clone pPM 1305 may be produced by partial digestion as described below. At present six fragments of pPM 1305 have been envisaged. These are designated plasmids pPM 1321, pPM 1322, pPM 1323, pPM 1324, pPM 1325, pPM 1326, pPM 1330 and pPM 2218. Samples of the plasmids are maintained in the Culture Collection of the Universith of Adelaide, North Terrace, Adelaide, South Australia. These are illustrated in Figure 6 below.
Accordingly in a further aspect of the present invention there is provide a DNA probe including a plasmid from which rfb DNA has been deleted and selected from plasmids pPM 1305, pPM 1322, pPM 1323, pPM 1324, pPM 1325, pPM 1326, pPM 1330 and pPM 2218 and mixtures thereof.
As described above the rfb,Q1 region has been subcloned into six parts and each has been used as a probe in Southern DNA hybridizations with a selection of E.coli and Sh.flexneri strains of different serotypes. This has enabled us to show that the different probes vary in their ability to react in a manner which shows serotype specificity. For example, Sh.flexneri strains all react with one probe whereas only serotypes 4a/y and 6 react with another and only 2a and 4 react with a third. The fragment sizes with which they react also differ markedly so that the pattern observed using several probes is quite distinctive for that particular serotype.
Using these same set of probes it was also possible to very rapidly subgroup E.coli strains of the 02 and 018 serotypes into exactly the same groups as had previously been defined by using an extensive series of tests, involving analysis of both LPS and outer membrane proteins and a large number of isoenzymes and one strain had been mistyped probably because of a mutation affecting the ability to produce a specific isoenzyme. The 02 serotype strain is important as it is implicated in such diseases as septicaemia n chickens and in urinary tract infections in man. (It is a particular advantage of this aspect of the present invention that the probes are effective at differentiating serotypes even when the gene products are not made.)
By the same approach we have also cloned the genes for the 02 rfb region. The plasmids pPA1343, pPA1344 and pPA1345 are examples of clones containing the 02 rfb region. Accordingly in a preferred form, there is provided a DNA probe including a plasmid selected from plasmids pPA1343, 1344 or 1345 or a digestion derivative thereof. This has great potential in the development of vaccines against diseases caused by Enteobacteriaceae where the O-antigen is a protective antigen, that is, where the protection is serotype specific. These clones also provide a basis for developing further probes. Similarly this approach has also been used to clone the genes for the 0157 rfb region. Plasmid pPM1354 represents an example of such a clone.
Accordingly in a preferred form, there is provided a DNA probe including a plasmid pPM1354, or a digestion derivative thereof. This clone has potential for both
vaccine development and for specific probes.
E.coli of the 0157 serotype are responsible for haemorrhatic uraemic syndrome and are referred to as
Enterohaemorratic E.coli and EHEC. This is a severe condition and can often lead to death, and vaccines against this disease are not presently available.
In summary, the advantages of such probes include: the presence of rfb and closely linked DNA can be detected even in the absence of gene expression, a problem which may arise if the O-antigen is incompatible with the core region of the recipient organism, or if the recipient is expressing its own O-antigen and effectively out-competing the O-antigen encoded by the cloned DNA; the identification of an rfb clone is greatly simplified; a restriction map of the region to be cloned can be determined beforehand by Southern DNA hybridization, and this could permit a better choice of restriction enzyme for cleaving the chromosomal DNA prior to cloning.
In addition the probes enabled us to differentiate two 0115 strains, one which was an enterotoxigenic E.coli (ETEC) and another which was associated with septicaemia. Thus, these results, with the 02, 018 and 0115 strains, illustrate that the probes may also enable us to differentiate organisms which are apparently of the same serotype but produce different diseases. This is extremely important because of course some E.coli serotypes are part of natural human bacterial flora.
The DNA probes according to the present invention may be labelled in any suitable manner. A radioactive or
non-radioactive label may be used. Where a radioactive labelled probe is used, radioactive isotopes of phosphorus or sulphur e.g. 32 phosphorus and 35 sulphur may be used. Where non-radioactive labelling is preferred, a biotinylated photo-sensitive label may be selected.
In a still further aspect of the present invention there is provided a method for preparing a DNA probe which method includes providing a plasmid cloning vector; a first restriction enzyme; and a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae; partially digesting the plasmid cloning vector with the restriction enzyme; and inserting the fragment of DNA into a restriction site.
The restriction site chosen may correspond to the restriction enzyme used or be compatible therewith.
The plasmid cloning vector may be of any suitable type* Tne plasmid cloning vector pHC79 has been found to be suitable. Since this plasmid cloning vector includes a BamHI restriction site, a corresponding BamHI or Sau 3A restriction enzyme is preferred.
In a preferred form, the ligated DNA so formed may be packaged in vitro and transduced into a suitable bacterial strain.
An E.coli strain may be used. An E.coli K-12 strain may be used. The E.coli K-12 strain DH1 has been found to be suitable. In a preferred aspect where subclones are required
the method of preparing a DNA probe may further include providing a plurality of restriction enzymes; and digesting the ligated DNA with the restriction enzymes to produce restriction fragments of differing size. The restriction enzymes may include Mlul, Kpn 1,
Sail, BamHI, Sad. PstI, Hpal, Clal, HindiII and the like.
Where the fragments include protruding ends, the fragments may be subjected to the further step of filling the protruding ends so formed. This may be undertaken utilizing the Klenow fragment of DNA polymerase 1.
The sub clones so formed may include the plasmids pPM 1321, pPM 1322, pPM 1323, pPM 1324, pPM 1325, pPM 1326, pPM 1330 and pPM 2218. The plasmids pPM 1321, pPM 1330 and pPM 1326 are preferred as they have been found to be highly conserved. It is hypothesized that the plasmids encode part of the region that specifies the OlOl serotype and may be associated with any common properties of the O-antigen chains that allow ETEC to be more efficient pathogens or inhabitants of the intestinal tract are likely to be found encoded in this region of the rfb cluster.
Accordingly in a further aspect of the present invention there is provided a method of diagnosing a disease which method includes providing a sample to be tested; and at least one DNA probe including a fragment of DNA which probe detects the presence of the rfb region of an Enterobacteriaceae; contacting the sample with the at least one DNA probe; and
_ _
subjecting the product thereof to an assay. In a preferred form of this aspect of the present invention the method of diagnosis may in addition provide a method of serotyping the organism responsible for the disease. In this form the method of diagnosis may include providing a series of samples to be tested; and a DNA probe kit including a first DNA probe including a fragment of DNA which detects the presence of the rfb region of an Enterobacteriaceae: and a second DNA probe including a fragment of
DNA which detects the presence of the rfb region of an Enterobacteriaceae in a manner different to said first probe such that the first and second probes are serotype specific; contacting each sample with a different DNA probe from the kit; and subjecting the products thereof to a series of assays.
The one such sample to be tested may be of any suitable type. A faecal sample may be used.
The or each DNA probe is preferably a radioactively or non-radioactively labelled DNA probe, as described above. The product may be assayed in any suitable manner.
A Western and/or color blot analysis may be used.
The plasmids including restriction fragments of DNA including substantially the whole of the rfb locus of an
Enterobacteriacae, for example plasmid pPM 1305 may be inserted into a suitable avirulent bacterial carrier strain
which may in turn function as a live vaccine. As stated above, where the Enterobacteriaceae is an E.coli of the 0101 serotype, we have found that a fragment having a minimum length of approximately 13 Kb and a maximum length of approximately 15.8 Kb is required for 0101 0-antigen biosynthesis when it is introduced into E.coli K-12.
Accordingly in a still further aspect of the present invention there is provided a method of preparing an avirulent strain of an enterobacterium which method includes providing a sample of a preselected bacterial strain; and a plasmid including a fragment of DNA containing genes encoding for the synthesis of the
O-antigen of an Enterobacteriaeae; and inserting the cloned genes on the plasmid into the chromosome of the preselected bacterial strain.
The plasmid may be plasmid pPM 1305.
The preselected bacterial strain may be selected from Salmonella and Shiqella strains. Salmonella tvphimurium. Salmonella typhi and Salmonella dublin have been found to be suitable.
Diseases of interest may include those generated by any enterobacterial strain.
The avirulent strain of an enterobacterium referred may provide the basis for a vaccine composition.
The vaccine composition may be used as a live oral vaccine against enteropathogenic diseases of man or domestic animals.
The genes for group- (rfb) and type-antigen biosynthesis of Shiqella flexneri may be introduced into the
preselected strain. Further changes may include introduction of the Shiαella LPS core biosynthesis genes (rfa) so that the strain expresses the O-antigen of the appropriate Shiqella specificity on the cell surface. Analysis of the LPS by silver staining, ELISA and haemagglutination inhibition may be used to assay the production of the O-antigen. Immunogenicity may be assessed in mice, and rabbits and ultimately monkeys.
Accordingly in a still further aspect of the present invention there is provided a vaccine composition useful for effecting immunity against diseases of an Enterobacteriaceae, including a bacterial carrier strain; and a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae, inserted into the chromosome of the bacterial carrier strain.
The bacterial carrier strain may be selected from Salmonella and Shiqella strains.
The Enterobacteriaceae is preferably an E.coli of the 0101 serotype and the fragment of DNA has a munimum length of approximately 8.9 kilobase pairs, and a maximum length of approximately 11.8 kilobase pairs.
Alternatively the Enterobacteriaceae is an E.coli of the 0157 or 02 serotype. The vaccine composition may be provided in any suitable form. The vaccine composition may be provided in an oral or injectable form. Suitable carriers including aqueous and/or alcoholic carriers may be included. A buffered saline solution may be used. Other recipients and compounding ingredients known per se in the art may be included if
desired.
In a further aspect of the present invention there is provided a method for the prophylactic treatment of diseases of an Enterobacteriaceae in mammals, including 5 humans, which method includes providing a mammal to be treated; and a vaccine composition useful for effecting immunity against diseases of an Enterobacteriaceae. including 0 a bacterial carrier strain; and a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an
Enterobacteriaceae. inserted into the chromosome of the bacterial carrier strain; and 5 administering to the mammal a prophylactically effective amount of the vaccine composition.
In a particularly preferred aspect of the present invention there is provided a method for the prophylactic treatment of diseases of E.coli of the 0157 serotype in o mammals, including humans, which method includes providing a mammal to be treated; and a vaccine composition including a Salmonalla or Shiqella carrier strain; and/or a fragment of DNA derived from plasmid pPM1354, or a digestion derivative thereof; and administering to the mammal a prophylatically effective amount of the vaccine composition. Q E.coli of the 0157 serotype are responsible for
haemorrhatic uraemic syndrome and are referred to as Enterohae orratic E.coli and EHEC.
This is a severe condition and can often lead to death, and vaccines against this disease are not presently available.
The present invention will now be more fully described with reference to the accompanying examples and drawings. It should be understood, however, that the description following is illustrative only and should not be taken in any way as a restriction on the generality of the invention described above.
In the Figures: Figure 1
Comparison by electrophoresis in SDS on 20% polyacrylamide gels of whole membrane material from H510a, B41, DH1, E963 (DHl[pPM1305]), VAC1676, KATI1706 and VC1751 by Western Blot analysis.
After electrophoretic transfer the LPS Material was visualized using 0101 typing serum raised against B41 (1:1000) followed by the addition of goat anti rabbit-IgG coupled to horseradish peroxidase and the addition of peroxidase substrate. Figure 2
Sarkosyl extracted membrane material from strains DH1, E11176, E963, H510a, B41, VAC1676, KATI1706, VC1751 and 8CE275/6 were solubilised in SDS and electrophoresed on 7-25% polyacrylamide exponential gradient gels as described in (10). The gels were fixed so that predominantly LPS or lipoproteins were stained with silver (28) .
Figure 3
Restriction endonuclease cleavage pattern and deletion analysis of plasmid pPM 1305. The thicker region corresponds to residual pHC79. Plasmid DNA of single and double digests were analysed in 0.8% and 1.0% agarose gels in TBE buffer. The lines indicate the extent of cloned DNA retained in each of the derivatives of pPM1305. Their ability to mediate synthesis of 0101 O-antigen is indicated. pPM 1305 was initially digested with Mlul and insert DNA ligated into the Mlul sites of pLG339 (Stoker et al. 1982) forming pPM1330. Plasmids pPM2218 and pPM2219 represent Sail and Hpal deletions of pPM1305. Plasmids of pPM2220 and PPM2221 were generated by and filling of the protruding ends after BamHI cleavage and by removing the protruding ends after digesting with Sad respectively.
Six DNA fragments defined by the PatI restriction endonuclease sites of pPM1305 were subcloned into the PatI silo of pGB2 (Churchward et al., 1904). Analysis of minimal coding region for the 0101 E.coli rfb region indicates that subclones pPM1322, pPM1324, pPM1325 and pPM1326 all contain rfb coding DNA, and that pPM 1321 and pPM1323 may contain a combination of flanking and rfb DNA. The thicker line represents residual pHC79 DNA. Figure 4 An autoradiograph of an SDS polyacrylamide gel
35 showing [ S]-labelled proteins produced from whole minicells carrying plasmid pPM1305 and the cloning vector pHC79. The exposure was for seven days at room temperature without fluorography.
- -
Figure 5
Autoradiographs showing Southern hybridisation analysis of restriction endonuclease-digested whole genomic
DNA from E.coli 0101 isolates, using (Pj-labelled pPM1322 (Panel A, Psi); Panel B, EcoRi) and pPM1324 (Panel C, EcoRi;
Panel D, PatI as probes. The stringency in the final washes of the nitrocellulose filter was 65°C in 2 x SSC. The developing time was 2d using Ilford intensifying screens at
-70°C. Figure 6
Chromosal DNA from serotypic variants of 018 and 02
E.coli was digested with restriction endonucleases PstI,
EcoRI and Hindlll in all combinations of single and double digests. The DNA samples were electrophoresed on 0.8% agarose and subsequently transferred to nitrocellulose by the method of Southern.
The two subclones pPM1321 and pPM1326 from the 0101 rfb clone pPM1305 are believed to represent a highly conserved region of DNA within the rfb gene cluster. These subclones were used as radio-labelled probes to detect restriction fragment length polymorphisms (RFlPs) within 018 and 02 E.coli.
The restriction maps obtained (D) from using these probes in Southern hybridisation analysis (A, B, C) show the high degree of relatedness between 018 and others not shown on E.coli and the probable close evolutionary relationships.
Figure 7
Chromosomal DNA from the Shigella flexneri strains
PE532, PE524, PE525, PE526 and PE527 corresponding to serotypes 2a, 4a, 6, 2a and 4a/y, respectively, as well as a
selection of randomly chosen E.coli strains of the serotypes indicated, were digested with Pstl. the fragments separated by electrophoresis in 0.8% agarose. The DNA was then transferred to nitrocellulose and replicates were probed in Southern DNA hybridization with the various subclonal fragments of pPM1305. The radiolabelled probes used were A (PPM1321); B (pPM1326); C (pPM1325); D (pPM1322); E (pPM1324) and F (pPM1323).
The hybridizations were performed at high stringency; 0.2 x SS C at 65°C. The autoradiography was exposed for 2 days at - 70°C using intensifying screens.
EXAMPLE 1 Bacterial strains Media All strains were routinely grown in Nutrient broth
(Difco Research Laboratories Detroit, Mich.) made at double strength with 5g/l NaCl added. Nutrient agar was blood agar base (Difco) without the additoin of blood. Where appropriate, ampicillin, media (25ug/ml) and tetracycline (lOug/ml) were added. Cultures for routine use were maintained as 15% glycerols at -20 C. Antiserum
Typing serum for 0101 raised against B41 in rabbits was obtained from C. Murray, IMVS, Adelaide. This was extensively adsorbed with E.coli K-12 strain DHL Preparation of genomic DNA
The isolation of genomic DNA was performed essentially as described by Manning et al (14) . Cells from a 20ml shaking Overnight culture were pelleted (3000xg; 10 min.) and washed once, the pellet treated with lysozyme and
then the sarkosyl lysing solution, followed by phenol and ether extraction. The DNA solution was then extensively dialysed against TE buffer (lOmM Tris-HKCl, ImM EDTA, pH 8.0). Plasmid DNA isolation As previously described in (14), this method is essentially a three step alkaline lysis, followed by CsCl centrifugation on a 2-step gradient (Garger et al 1983). Transformation of Plasmid DNA
Transformation of E.coli K-12 strains was perfomred as previously described (9). Competent cells were made by
MgC -CaC incubation on ice. Although cells were assumed to be competent after 60 min. on ince, they were routinely left overnight on ice.
Competent cells (0.2ml) were mixed with 1 ug DNA, incubated on ice for 30 min, then heat shocked (42°C) for 2 min. The cells were then allowed to express in nutrient broth for 60 min. at 37°C with shaking and the mixture plated onto the appropriate antibiotic plate. Molecular cloning
Using genomic DNA from B41, a cosmid library was constructed as previously described (14) . 1-2 ug of genomic DNA partially digested with Sau3A was cloned into the BamHI site of 6 ug alkaline phosphatase treated BamHI digested pHC79 DNA. The ligated DNA was packaged in vitro and transducted into E.coli K-12 strain DHL This procedure usually yielded 1000-2000 ampicillin resistant colonies. Minicell analysis and autoradiography
Plasmids were transformed into the minicell producing stran DS410. Minicells were purified on sucrose gradients and the plasmid encoded proteins were labelled with
-x c t S3-methionine and solubilized in sample buffer as previously described (13) . After electrophoresis in SDS on 11-20% polyacrylamide gels, the dried gel was subjected to autoradiography using Kodak X-omat film at room temperature. Restriction analysis
Restriction enzyme digestion of DNA was carried out as recommended by the manufacturers. The digested DNA was analysed in horizontal 0.8% w/v agarose gel system in TBE buffer (67mMTris, 22mM Boric acid, 2mM EDTA ρH8.8). All gels for size determination of plasmid DNA fragments or restriction endonuclease digested genomic DNA for Southern transfer were electrophoresed overnight at 20v. Gels were stained in ethidium bromide (2ug/ml) and visualized under UV light. The sizes of restriction fragments were determined by their relative mobility to Bacillus subtilis bacteriophage SPP1 DNA cut with EcoRi 22) . End filling with Klenow fragment
Protuding ends created by cleavage with BamHI and SacI were filled or removed using the Klenow fragment of DNA polymerase I. Typically, 1.6ug of digested DNA, 2 ul of each dNTP (2mM) and 5 units of Klenow fragment (Pharmacia) were mixed and left at room temperature for 30 min. The reaction was stopped by the addition of lul of -.5mM EDIA and incubation at 65°C for 15 min. Unincorporated dNTPs and enzyme were removed by centrifugation through a Sepharose C1-6B column.
SDS-Polvacrylamide gel electrophoresis (SDS-PAGE) and silver staining for lipopolysaccharide
Analyses of lipopolysaccharides on SDS-PAGE and the preparation of samples is identical to that of Kusecek et al.
_ _
(1984). Strains for analysis were grown in 100 ml of L-broth. The cell envelopes were extracted with sarkosyl to enrich for outer membranes (Achtman et al., 1983). After suitable dilution, these were loaded onto 7-25% exponential gradient gels and run at 10mA for 16h. Silver staining for lipopolysaccharide was carried out according to Tsai and Frasch (1982). Western and Colony Blot Analysis
Colony and Western blots were performed using a 1:1000 dilution of 0101 typing serum as primary antiserum. The secondary antiserum was goat anti-rabbit IgG coupled to horseradish peroxidase (Nordic Immunology) at 1:5000 final dilution. The methods in detail have been described previously (Manning et al. 1986). Protein A-colloidal gold
Colloidal gold particles (c. 15-20nm) were prepared using the citrate method as described (de Mey and Meormans, 1986) and conjugated with Protein A (Pharmacia) . Immunoqold labelling of whole cells
Cells grown on CFA agar for 18h at 37°C were resuspended and washed once in phosphate-buffered saline (pH 7.2) containing 1% bovine serum albumin (Fraction V, FLow Laboratories, North Ryde, Australia) (PBS + BSA) . A drop (35 ul) of cell suspension was placed on a sheet of parafilm. A poly-t-lysine treated formvar electron microscope grid was then placed plastic side down on the surface of this drop for 2 min. (Mazia et al 1978). This grid was then transferred to drops of the following reagents placed on the same parafilm sheet: PBS + BSA x 2; antibody (1:200 dilution in saline) for 15 min.; PBS + BSA x 3; Protein A-gold (1:50 dilution in
PBS + BSA); distilled wter x 3. After completing the protocol, excess fluid was removed from the grid and the grid allowed to air-dry without negative staining. In some experiments, immunogoId-labelled preparations were negatively stained with a solution of 2% w/v uranyl acetate. Grids were examined in a JEOL JEM 100S transmission electron microscope operated with an accelerating voltage of 80kV. Nick Translation of PPM1305 and Southern Analysis
Plasmid DNA was Nick translated with DNA Polymerase i and Southern DNA hybridization analysis (Southern, 1975) was carried out according to a modification of Maniatis et.al. (1982). [32p3 labelled DNA of pPM1305 and its subclones were used to probe suitably digested genomic DNA from a number of 0101 isolates. Autoradiography was carried out at -70°C on Kodak X-omat film, with intensifying screens. The exposure time was 3 days.
RESULTS Molecular cloning of (rfb) region for 101 LPS biosynthesis
Genetic evidence from E.coli. Salmonella and Vibrio cholerae demonstrates that the genes for the biosynthesis of the O-antigen is determined by a gene cluster referred to as the rfb (Nikaido et al. , 1987; Brahmbatt et al. 1986; Manning et al. 1986; Ward et al 1987). Thus, a cosmid genomic library of approximately 1000 colonies was screened using 0101 typing serum, made against type strain B41 (Orskov et al. , 1987), and which had been extensively adsorbed with E.coli K-12 strain DHL We detected 13 clones demonstrating various degrees of reactivity on colony blot. Initial Western blot analysis of whole membrane material showed that the majority of the clones owed their reactivity to the
expression of cloned genes for proteins (data now shown) . However, one strain, DHl (pPM1301) produced a smear-like pattern, suggesting that it could mediate the expression of genes responsible for synthesis of LPS-like material. This clone was confirmed as 0101 serotype by the E.coli reference laboratory of the Institute of Medical and Veterinary Science in Adelaide, South Australia. Western blot analysis of whole-membrane material from DHl (pPM1305) a subclone of pPM1301 (see below) along with other known 0101 E.coli isolates using antiserum raised against B41 revealed that indeed DHl harbouring pPM1305 produces LPS O-antigen material similar in reactivity to the other 0101 isolates (data not shown) . Immunogold electron microscopy using the 0101 typing serum demonstrates that not only is the O-antigen of the appropriate specificity but also that it is surface-located in a similar fashion to B41 (Figure 1).
When sarkosyl-extracted membrane material is run in SDS on 7-25% polyacrylamide exponential gradient gels, there are variations in the O-antigen banding patterns of different 0101 isolates (Figure 2). For example, type strain H510a (Orskov et al., 1977) appears as a series of doublets of slightly different electrophoretic mobility. The E.coli K-12 strains harbouring pPM1305 and pPM1330 (a low copy number plasmid; see below) exhibit a singlet banding pattern which differs somewhat from the pattern of B41, although it still reacts with 0101 antiserum on a Western blot (data not shown) . These differences presumably reflect a difference in lipopolysaccharide core composition or incomplete expression or modification in E.coli K-12.
_ _ .
Restriction analysis of cloned DNA
The cosmid pPM1301 was reduced in size in a two stage process: a partial Hindlll digestion to produce
PPM1302 followed by a subsequent partial Mlul digestion to
5 give pPM1305. A restriction map of pPM1305 which contains
16.4kb of cloned DNA, is shown in Figure 3.
A more accurate estimate of the minimal coding region of 1010 O-antigen biosynthesis in pPM1305 was determined by subcloning a series of fragments into low copy 0 number vector pLG339 (Stoker et al., 1982) and by constructing a series of derivatives (Figure 3) . Only plasmids pPM1330 (Mlul-Mlul subclone) and pPM2218 (Sail deletion) expressed O-antigen, as judged by silver staining for LPS (Figure 2) . pPM1330 also exhibits superior plasmid 5 stability compared to pPM1305 (data not shown) . NOne of the other derivatives produced detectable levels of O-antigen (Figure 3). Therefore the coding region of the 0101 rfb gene cluster must extend from the region defined by the Sall-Hpal restriction endonuclease sites at (6.0-7.3kb) to the region o between the Sacl-Mlul sites (at 16.2-17.8 kb) ; i.e. a minimum of 8.9 kb and a maximum of 11.8 kb of DNA is required for
O-antigen biosynthesis.
35 Analysis of ϊ S3 - labelled proteins encoded bv pPM1305 in minicells 5 Examination of the proteins encoded by pPM1305 in minicells revealed six new polypeptides produced in various amounts with sizes of 80, 79, 52, 42, 38 and 24 kD (Figure 4) . The sum of the sizes of these proteins would require a coding region of about 9kb of DNA, assuming there are no 0 overlaps and no non-coding regions between the structural
genes. This correlates very closely to the amount of DNA required for antigen biosynthesis. Since [ 35S]-methionine was used, it is also possible that proteins lacking methionine or produced in very low amounts are also involved in 0101 synthesis and have not been detected. It has not been possible to determine whether all of these proteins have a role in O-antigen biosynthesis. Attempts using transposon insertion analysis have invariably resulted in the simultaneous generation of deletion plasmids, none of which expresses O-antigen (data not shown) .
DNA hybridization analysis using subclones of pPM1305 as probes . Colony hybridization analyses using [ 32P3 labelled pPM1305 as a probe were performed to determine whether this plasmid is useful as a specific probe for 0101 rfb region. These experiements (data not shown) revealed that pPM1305 could hybridize (in most cases weakly) to all
E.coli isolates tested, regardless of the O-serotype. There was no hybridization with eithr V.cholerae, Salmonella or the E.coli K-12 rfb delete strain, QE35 (Sunshine and Kelly, 1971) . Interestingly, this probe reacts strongly with several apparently immunologically unrelated serotypes and the basis for this is being examined.
In order to determine whether the differences in O-antigen banding pattern on SDS-PAGE gels are reflected at the DNA level in the rfb locus, the six PatI fragments of PPM1305 were subcloned into vector pGB2 (Churchward et al., 1984) (Figure 3). Southern hybridization analyses using selected subclones as probes are shown in Figure 5. The two largest PstI fragments, pPM1322 and pPM1324,
known to be required for O-antigen biosynthesis were used to determine the level of homology in the rfb locus among other 0101 isolates. When the largest probe pPM1322 is employed, htere appears to be extensive conservation of restriction sites in the rfb region of B41 and the other ETEC isolates as well as isolate 8CE275/B (non-ETEC) . Strain H510a (non-ETEC) does not appear to show the same level of homology with B41 as the other isolates. Strain B41 itself, whilst sharing common restriction fragments with the other isolates, also shows evidence of DNA sequence duplication. When pPM1324 is used, the close relationship with the other 0101 isolates with the exception of strain H510a is evident, as is sequence duplication in B41. The control strains QE35 (rfb delet) and DHl have no sequences in common with these probes.
The results of the Southern hybridization analysis using the two largest internal probes pPM1322 and pPM1324 with the 0101 isolates and E.coli K-12 strains Q35 and DHl are shown in Figures 6 and 7.
Figure 6 shows that when pPM1322 is used as a probe under conditions of high stringency, this fragment appears to be highly conserved among all isolates. The strain H510a, which has a unique LPS banding pattern, while hybridizing with sequences on pPM1322 exhibits a markedly different pattern of fragments, not surpisingly there is no detectable homology with the rfb delete strain Q35 or the E.coli K-12 host strain DHL
Figure 7 shows that when pPM1324 is used as a probe under the same conditions as pPM1322, H510a exhibits a unique pattern, whereas 8CE275/6, VAC1676 and VC17651 exhibit identical patterns. Strains B41 and KAT11706 have a fragment
in common with the other isolates (except H510a) . No hybridization is seen with strains Q35 or DHl. Interestingly, this probe fails to detect an identical fragment in B41, suggesting that all of the cloned DNA in ρPM1323 and pPM1324 is not contiguous, probably due to the deletion process by which they were generated. Discussion
We have described the cloning and expression in E.coli K-12 of the rfb region derived from an Enterotoxigenic E.coli of the 0101 serotype. The LPS expressed by the two clones, DHl (pPM1305) and DHl(ρPM1330) is significantly different electrophoretically from that of the parent strain B41. This may be because of a different host genetic background, possibly reflecting a difference in the LPS core structure. It is already known that several different core structures exist in E.coli (for a review, see Luderitz et al, 1982) . It may also reflect modification of the O-chain by strain DHl.
At least six proteins are encoded within the minimal coding region, implicating them in the synthesis and assembly of the O-subunit. Production of the 0101 O-antigen as LPS in an rfb delete strain QE35 implies that only the rfb genes carried by the clones are necessary for its expression and assembly on the E.coli K-12 core (data not shown). Since both structure of 0101 LPS is unknown, and the precise minimal coding region is not defined, it is not possible to say whether all of the proteins expressed in minicells or other additional undetected proteins are required for the synthesis of 0101 O-antigen. Subcloning and deletion analysis suggests that the predicted 9kb required for the
_ _
synthesis of these proteins is a good estimate of the minimal amount of coding DNA.
The 0101 isolates that we have examined appear to exhibit some variability in the LPS, as judged by SDS-PAGE. This difference is not detected serologically with polyvalent antiserum. There are no reports in the literature of 0101 serotype variants, despite the fact that it is a common animal ETEC serotype. It is not yet possible to speculate on the chemical relationships between the different 0101 patterns. The genetic relatedness, as judged by DNA hybridization, one may predict that these differences may simply reflect minor modifications in the O-chain. Current data suggest that multiple 0101 LPS types exist: one type defined by H510a and other types observed in B41, KATH706, 8CE275/6, VAC1676 and VC1751. The DNA hybridization data suggest that the enzymes involved in H510a LPS biosynthesis are less closely related to the other types which share common restriction fragments. The distinct LPS pattern on SDS-PAGE of B41 may reflect the sequence of gene duplication that we have observed in this strain, since the clones of the rfb region of B41, i.e. DHl(pPM1305) and DHl(pPM1330) more closely resemble the LPS patterns of the other 0101 isolates.
The possibility tha 0101 E.coli belongs to the "clonal" groupings described by Achtman and Plsuchke (1986) has yet to be explored. It is possible that the non-H510a LPS types form a closely related "clonal" grouping that is often found in association with a specific disease in animals, and so the disease may be considered as part of the "clonal" character of the strain. Subclones of pPM1305 show homology to strains not of
_ _
the 0101 serotype and may be useful in determining the relationships between strains of serotypes other than 0101. Since these probes can hybridize to serologically unrelated serotypes (data not shown; Beger et al. , 1988), they may also form the basis for developing rapi diagnostic probes capable of differentiating disease-causing organisms from the commensal flora of the same serotype. Conventional serotyping has not provided a means of identifying disease-causing organisms. The detection of O-serotype variants by DNA hybridization analysis may provide a more specific method for identifying pathogenic organisms.
The availability of cloned rfb 0101 genes also provides a basis for the construction of a hybrid vaccine strain in avirulent Salmonella (Stevenson and Manning, 1985), since it has been documented that antibodies to 0101 are more hghly protective against 010LK99/F41 challenge than antibodies to the colonization factors or adhesins K99 or F41 (Duchet-Suchaux, 1986).
TABLE 1
Bacterial Strains
Strain Genotype/Phenotype Source
DHl F" "gyrA96.recAl,endAl.thi-1.hsdR17.SUPE B.Bachmann
QE35 delratt2PH-mgl387.relAl,SPOTLthi-L B.Bachmann
DS410 F~.minA.minB,rpsL D. Sherratt
B41 0101:K99/F41 F. and I. Orskov
H510a 0101:H33 F. and I. Orskov
8CE275/6 010LK103 F. and I. Orskov
VAC1676 0101:K30:H~(3P") H. Moon
KATI1706 0101:K30:H~(3P~) H. Moon
VC1751 0101:K27:H~(3P~) H. Moon
E963 DHl(pPM1305);amlr;0101-Oag+ This study
E1176 DHl(pPM1330);tetr;0101-Oag+ This study
E1159 DHl(pPM1321) ;Spcr;strr This study
E1160 DHl(pPM1322);Spcr;strr This study
E1161 DHl(pPM1323);Spcr;strr This study
E1197 DHl(pPM1324);Spcr;strr This study
E1198 DHl(pPM1325);Spcr;strr This study
E1199 DHl(pPM1326);Spcr;strr This study
E1102 DHl(pPM1329);tetr This study
E1203 DHl(pPM1331) ;tetr This study
E1204 DHl(pPM1332) ;tetr This study
E1205 DHl(pPM1333) ;tetr This study
E1206 DHl(pPMΪ334);tetr This study
_ _
LITERATURE CITED
(1) Achtman, M. , M. Heuzenroeder, B. Kusecek, H. Ochman, D. Caugant, R.K. Selandler, V. Vuisanen-Rhen, T.K. Korhonen, S. Stuart, F. Orskov and I. Orskov, 1986. Clonal Analysis of Escherichia coli 02:K1 isolated from diseased humans and animals. Infect. Immun. 51 : 228 - 276.
(2) Achtman, M., and G. Pluschke, 1986. Clonal analysis of descent and virulence among selected Escherichia coli. Ann. Rev. Microbiol. 40 : 185 - 210.
(3) Awad-Massalmeh, M. , H.W. Moon, P.L. Runnels and R.A. Schneider, 1982. Rilus production, hemagglutination, and adhesion of porcine strains of enterotoxigenic Escherichia coli lacking K88, K99 and 987P antigens. Infect. Immun, 35 : 305-313.
(4) Brahmbatt, H.N., N.B. Quigley and P.R. Reeves, 1986. Cloning part of the region encoding biosynthetic enzymes for surface antigen (O-antigen) of Salmonella typhimurium. Mol. Gen. Genet. 203 : 172-176.
(5) Brown, M.C.M. , A. Weston, J.R. Saunders and G.P. Humphreys, 1979. Transformation of E.coli C600 by plasmid DNA at different phases of growth. FEMS. Microbiol. Lett. 5 : 219-222.
(6) Churchwald, G., D. Belin and Y. Nagamine. 1984. A pSClOl derived plasmid which sows no sequence homology to other commonly used cloning vectors. Gene. 31 : 165-171.
(7) Hanahan, D., 1983. Studies on transformation of Escherichia coli with plasmids. J. Mol. Biol. 166 :
557-580.
(8) Hohn, B., and J. Collins, 1980. A small cosmid for cloning of large DNA fragments. Gene 11 : 291-298.
(9) Kauffmann, F. 1947. The serology of the coli group. J. Immunol. 57 : 71-100.
(10) Kusecek, B., H. Wloch, A. Mercer, V. Vaisanen, G. Pluschke, T. Korhonen and M. Achtman, 1984. Lipopolysaccaride capsule and fimbriae as virulence factors among 01, 07, 016, 018, 075, and Kl, K5 or K100 Escherichia coli. Infect. Immun. 43 : 368-379.
(11) Levine, M.M. , 1987. Escherichia coli that cause Diarrhea : Enterotoxigenic, Enteropathogenic, Enteroinvasive, Enterohemorrhagic and Enteroadherent. J. Infect. Dis. 155 : 377-389. (12) Maniatis, T., Fritsch, E.F., and Sambrook, J. 1982. Molecular Cloning: A laboratory manual. Cold Spring Harbour Laboratory, Cold Spring Harbour.
(13) Manning, P. ., M.H. Brown, and M.W. Heuzenroeder, 1984. Cloning of the structural gene (hly) for the haemolysin of Vibrio cholerae El tor strain 017.
Gene. 31 : 225-231.
(14) Manning, P.A., M.W. Heuzenroeder, J. Yeadon, D.I. Leavesley, P.R. Reeves and D. Rowley, 1986. Molecular cloning and expression in Escherichia coli K-12 of the O-antigens of the Inaba and Ogawa serotypes of the Vibro cholerae 01 lipopolysaccarides and their potential for vaccine development. Infect. Immun. 53 : 272-277.
(15) Morris, J.A., and W.J. Sojka, 1985. Escherichia coli as a pathogen in animals. pp 47077 in The
Virulence of Escherichia coli : Reviews and Methods. M. Sussman, Ed., Academic Press, (London).
(16) Nikaido, H., K. Nikaido and P.M. Makela, 1966. Genetic determination of enzymes synthesizing O-specific sugars of the Salmonella lipopolysaccharide. J. Bacteriol. 91: 1126-1135.
(17) Orskov, I., F. Orskov, B. Jann, and K. Jann, 1977. Serology, chemistry and genetics of 0 and K antigens of Escherichia coli. Bacteriol. Rev. 1 : 667-710.
(18) Osborn, M.J., 1979. Biosynthesis and assembly of the lipopolysaccharide of the outer membrane, PP15-34. In M. Inouye (Ed)., Bacterial outer membranes, John Wiley and Sons, Inc., New York.
(19) Osborn, M.J., and H.C.P. Wu, 1980. Proteins of the outer membrane of gram negative bacteria. Annu.
Rev. Microbio. 34 : 369-422.
(20) Pluschke, G., A. Moll, B. Kusecek and M. Achtman, 1986. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and monoclonal antibodies as tools for the sub-grouping of Escherichia coli lipopoly¬ saccharide 018 and 023 antigens. Infect. Immun. 51 : 286-293.
(21) Ratcliff, S.W., J. Lub, A.T. Ganesan, B. Behrens., R. Thompson, M. Montenegro, G. Morelli and T.A. Trautner, 1979. The genome of B. subtilis phage
SPP1: the arrangement of restriction endonuclease generated fragments. Mol. Gen. Genet. 168 : 165-172.
(22) Smith, H.R., S.M. Scotland and B. Rowe, 1985. Genetics of Escherichia coli virulence. pρ227-269 in The Virulence of Escherichia coli : Reviews and
Methods. M. Sussman, Ed., Academic Press (London). (23) Stoker, N.G., N.F. Fairweather and B.G. Spratt, 1982. Versatile low copy number plasmid vectors for cloning in Escherichia coli: Gene 18: 335-341. (24) Stocker, B.A.D., and P.H. Makela, 1971. Genetic aspects of biosynthesis and structure of Salmonella lipopolysaccaride pp.369-438. In G. Weinbaum, S. Kadis and S.J. Ajl (Ed.), Microbial Toxins, Vol.IV, Academic Press Inc., London. (25) Sunshine, M.G., and B. Kelly, 1971. Extent of host deletions associated with bacteriophase P2-mediated education. J. Bacteriol. 108 : 695-704.
(26) Sussman, M. , 1985. Escherichia coli in human and animal disease, pp7-45 in The Virulence of Escherichia coli Reviews and methods- M. Sussman,
Ed., Academic Press (London).
(27) Tsai, C-M. , AND E. Frasch, 1982. A sensitive silver stain for detecting lipopolysaccharide in polyacrylamide gels. Anal. Biochem. 119 : 115-119.
(28) Ward, H.M., G. Morelli, M. Kamke, R. Morona, J. Hackett and P.A. Manning. 1987. A physical map of the choromosdomal region determining O-antigen biosynthesis in Vibrio cholerae 01. Gene 55 : 197-204. Finally, it is to be understood that various other modifications and/or alterations may be made without departing from the spirit of the present invention as outlined herein.
Claims
1. A DNA probe including a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae. which probe detects the presence of the rfb region of an Enterobacteriaceae.
2. A DNA probe according to claim 1 wherein the fragment of DNA contains genes encoding for the synthesis of the O-antigen of the 0101, 0156 or 02 serotype of an Escherichia coli.
3. A DNA probe according to claim 2 wherein the 0 fragment of DNA contains genes encoding for the synthesis of the O-antigen of the 0101 serotype of an Enterotoxigenic Escherichia coli.
4. A DNA probe according to claim 3 wherein the DNA fragment has a minimum length of approximately 8.9 kilobase 5 pairs and a maximum length of approximately 11.8 kilobase pairs.
5. A DNA probe kit including a first DNA probe including a fragment of DNA containing genes encoding for the synthesis of the O-antigen o of an Enterobacteriaceae, which probe detects the presence of the rfb region of an Enterobacteriaceae: and a second DNA probe including a fragment of DNA which detects the presence of the rfb region of an Enterobacteriaceae in a manner different to said first probe, 5 such that the first and second probes are serotype specific.
6. A DNA probe including a plasmid cloning vector; and a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae inserted 0 into a suitable site in the plasmid cloning vector.
7. A DNA probe according to claim 6 wherein the DNA fragment contains genes encoding for the synthesis of the O-antigen of the 0101 serotype of an Enterotoxigenic Escherichia coli and has a minimum length of approximately 8.9 kilobase pairs and a maximum length of approximately 11.8 kilobase pairs; and wherein the plasmid cloning vector is the plasmid cloning vector pHC79.
8. A DNA probe according to claim 6, further including a radioactive of non-radioactive label.
9. A DNA probe including a plasmid from which rfb DNA has been deleted, selected from plasmids pPM 1305, pPM 1322, pPM 1323, pPM 1324, pPM 1325, pPM 1326, pPM 1330 and pPM 2218 as hereinbefore described, and mixtures thereof.
10. A DNA probe containing genes encoding for the synthesis of the O-antigen of an Escherichia coli of the 0157 serotype and including a plasmid pPM 1354, or a digestion derivative thereof.
11. A DNA probe containing genes encoding for the synthesis of the O-antigen of an Escherichia coli of the 02 serotype and including a plasmid selected from plasmids pPA 1343, pPA 1344 or pPA 1345, or a digestion derivative thereof.
12. A method for preparing a DNA probe which detects the presence of the rfb region of an Enterobacteriaceae. which method includes providing a plasmid cloning vector; a first restriction enzyme; and a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae; partially digesting the plasmid cloning vector with the restriction enzyme; and ligating the fragment of DNA into a restriction site on the plasmid cloning vector.
13. A method according to claim 12, further including providing a plurality of restriction enzymes; and digesting the ligated DNA with the restriction enzymes to produce restriction fragments of differing size.
14. A method according to claim 13, wherein the restriction enzymes are selected from Mlul. Kpn 1, Sail. BamHI. Sad. PstI, Hpal, Clal and Hindlll.
15. A method of diagnosing a disease, which method includes providing a sample to be tested; and at least one DNA probe including a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae. which probe detects the presence of the rfb region of an Enterobacteriaceae; contacting the sample with the at least one DNA probe; and subjecting the product thereof to an assay.
16. A method according to claim 15, wherein the sample is a faecal sample; the at least one DNA probe is a radioactively or non-radioactively labelled DNA probe; and the assay is selected from Western and/or color blot analysis thereof.
17. A method of serotyping an organism responsible for a disease, which method includes providing a series of samples to be tested; and a DNA probe kit including a first DNA probe including a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae. which probe detects the presence of the rfb region of 0 an Enterobacteriaceae: and a second DNA probe including a fragment of
DNA which detects the presence of the rfb region of an Enterobacteriaceae in a manner different to said first probe, such that the first and 5 second probes are serotype specific; contacting each sample with a different DNA probe from the kit; and subjecting the product thereof to a series of assays.
18. A method of preparing an avirulent strain of an o enterobacterium which method includes providing a sample of a preselected bacterial strain; and a plasmid including a fragment of DNA containing genes encoding for the synthesis of the 5 O-antigen of an Enterobacteriaceae: and inserting the cloned genes on the plasmid into the chromosome of the preselected bacterial strain.
19. A method according to claim 18, wherein the preselected bacterial strain is selected from Salmonella and 0 Shigella strains.
20. A method according to claim 19 wherein the Enterobacteriaceae is an E.coli of the 0101 serotype and the fragment of DNA has a minimum length of approximately 8.9 kilobase pairs, and a maximum length of approximately 11.8 kilobase pairs.
21. A method according to claim 19 wherein the Enterobacteriaceae is an E.coli of the 0157 or 02 serotype.
22. A vaccine composition useful for effecting immunity against diseases of an Enterobacteriaceae. including a bacterial carrier strain; and a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an Enterobacteriaceae. inserted into the chromosome of the bacterial carrier strain.
23. A vaccine composition according to claim 22 wherein the bacterial carrier strain is selected from Salmonella and
Shigella strains.
24. A vaccine composition according to claim 23 wherein the Enterobacteriaceae is an E.coli of the 0101 serotype and the fragment of DNA has a minimum length of approximately 8.9 kilobase pairs, and a maximum length of approximately 11.8 kilobase pairs.
25. A vaccine composition according to claim 23 wherein the Enterobacteriaceae is an E.coli of the 0157 or 02 serotype.
26. A method for the prophylactic treatment of diseases of an Enterobacteriaceae in mammals, including humans, which method includes providing a mammal to be treated; and a vaccine composition useful for effecting immunity against diseases of an Enterobacteriaceae. including a bacterial carrier strain; and a fragment of DNA containing genes encoding for the synthesis of the O-antigen of an
Enterobacteriaceae, inserted into the chromosome of the bacterial carrier strain; and administering to the mammal a prophylactically effective amount of the vaccine composition.
27. A method according to claim 26 wherein the bacterial carrier strain of the vaccine composition is selected from Salmonella and Shigella strains.
28. A method according to claim 27 wherein the Enterobacteriaceae is an E.coli of the 0101 serotype and the fragment of DNA has a minimum length of approximately 8.9 kilobase pairs, and a maximum length of approximately 11.8 kilobase pairs.
29. A method according to claim 27 wherein the Enterobacteriaceae is an E.coli of the 0157 or 02 serotype.
30. A method for the prophylactic treatment of diseases of E.coli of the 0157 serotype in mammals, including humans, which method includes providing a mammal to be treated; and a vaccine composition including a Salmonella or Shigella carrier strain; and a fragment of DNA derived from plasmid PPM1354, or a digestion derivative thereof; and administering to the mammal a prophylactically effective amount of the vaccine composition.
31. A method according to claim 30 wherein the disease is haemorrhatic uraemic syndrome.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK037990A DK37990A (en) | 1988-06-20 | 1990-02-13 | DNA PROBE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPI8854 | 1988-06-20 | ||
AUPI885488 | 1988-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989012693A1 true WO1989012693A1 (en) | 1989-12-28 |
Family
ID=3773163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1989/000268 WO1989012693A1 (en) | 1988-06-20 | 1989-06-20 | Serotyping dna probes |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0377711A1 (en) |
JP (1) | JPH03501326A (en) |
DK (1) | DK37990A (en) |
WO (1) | WO1989012693A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0564689A1 (en) * | 1992-04-10 | 1993-10-13 | SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN | Recombinant live vaccines against Gram-negative enteric pathogens |
EP0652291A1 (en) * | 1992-07-07 | 1995-05-10 | Fuso Pharmaceutical Industries Ltd. | Probe for diagnosing infectious disease |
US5654417A (en) * | 1995-04-14 | 1997-08-05 | Children's Hospital And Medical Center | Nucleic acid probes for detecting E. coli O157:H7 |
WO1998050531A1 (en) * | 1997-05-01 | 1998-11-12 | The University Of Sydney | Nucleic acid molecules specific for bacterial antigens and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3890085A (en) * | 1984-02-01 | 1985-08-27 | Enterovax Limited | Genetically engineered bacteria useful as a vaccine |
AU7459987A (en) * | 1986-06-23 | 1988-01-07 | Schweiz. Serum - & Impfinstitut Und Institut Zur Erforschung Der Infektionskrankheiten ( Swiss Serum and Vaccine Institute and Institute for the Research of Infectious Diseases) | DNA fragments encoding the chromosomal nucleotide sugar synthetases and glycosyltransferases involved in the biosynthesis of the o-antigen of shigella dysenteriae, recombinant DNA molecules containing said fragments, host organisms containing said recombinant DNA molecules vaccines for preventing bacillary dysentery and method for preventing bacillary dysentery |
AU7626987A (en) * | 1986-08-19 | 1988-02-25 | Enterovax Research Pty. Ltd. | Hybrid bacterial strain |
-
1989
- 1989-06-20 JP JP1506630A patent/JPH03501326A/en active Pending
- 1989-06-20 WO PCT/AU1989/000268 patent/WO1989012693A1/en not_active Application Discontinuation
- 1989-06-20 EP EP89907053A patent/EP0377711A1/en not_active Withdrawn
-
1990
- 1990-02-13 DK DK037990A patent/DK37990A/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3890085A (en) * | 1984-02-01 | 1985-08-27 | Enterovax Limited | Genetically engineered bacteria useful as a vaccine |
AU7459987A (en) * | 1986-06-23 | 1988-01-07 | Schweiz. Serum - & Impfinstitut Und Institut Zur Erforschung Der Infektionskrankheiten ( Swiss Serum and Vaccine Institute and Institute for the Research of Infectious Diseases) | DNA fragments encoding the chromosomal nucleotide sugar synthetases and glycosyltransferases involved in the biosynthesis of the o-antigen of shigella dysenteriae, recombinant DNA molecules containing said fragments, host organisms containing said recombinant DNA molecules vaccines for preventing bacillary dysentery and method for preventing bacillary dysentery |
AU7626987A (en) * | 1986-08-19 | 1988-02-25 | Enterovax Research Pty. Ltd. | Hybrid bacterial strain |
Non-Patent Citations (10)
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0564689A1 (en) * | 1992-04-10 | 1993-10-13 | SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN | Recombinant live vaccines against Gram-negative enteric pathogens |
EP0652291A1 (en) * | 1992-07-07 | 1995-05-10 | Fuso Pharmaceutical Industries Ltd. | Probe for diagnosing infectious disease |
EP0652291A4 (en) * | 1992-07-07 | 1999-08-18 | Fuso Pharmaceutical Ind | Probe for diagnosing infectious disease. |
EP1160334A2 (en) * | 1992-07-07 | 2001-12-05 | Fuso Pharmaceutical Industries Ltd. | Probe for diagnosing infectious disease arising from Pseudomonas aeruginosa |
EP1167544A2 (en) * | 1992-07-07 | 2002-01-02 | Fuso Pharmaceutical Industries Ltd. | Probe for diagnosing infectious disease arising from Escherichia coli, Klebsiella pneumoniae or Enterobacter cloacae |
EP1160334A3 (en) * | 1992-07-07 | 2004-01-02 | Fuso Pharmaceutical Industries Ltd. | Probe for diagnosing infectious disease arising from Pseudomonas aeruginosa |
EP1167544A3 (en) * | 1992-07-07 | 2004-03-03 | Fuso Pharmaceutical Industries Ltd. | Probe for diagnosing infectious disease arising from Escherichia coli, Klebsiella pneumoniae or Enterobacter cloacae |
US5654417A (en) * | 1995-04-14 | 1997-08-05 | Children's Hospital And Medical Center | Nucleic acid probes for detecting E. coli O157:H7 |
WO1998050531A1 (en) * | 1997-05-01 | 1998-11-12 | The University Of Sydney | Nucleic acid molecules specific for bacterial antigens and uses thereof |
AU734022B2 (en) * | 1997-05-01 | 2001-05-31 | University Of Sydney, The | Nucleic acid molecules specific for bacterial antigens and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0377711A1 (en) | 1990-07-18 |
DK37990D0 (en) | 1990-02-13 |
DK37990A (en) | 1990-04-03 |
JPH03501326A (en) | 1991-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mariani-Kurkdjian et al. | Identification of a clone of Escherichia coli O103: H2 as a potential agent of hemolytic-uremic syndrome in France | |
Batisson et al. | Characterization of the novel factor paa involved in the early steps of the adhesion mechanism of attaching and effacing Escherichia coli | |
Adu-Bobie et al. | Detection of intimins α, β, γ, and δ, four intimin derivatives expressed by attaching and effacing microbial pathogens | |
Moseley et al. | Detection of enterotoxigenic Escherichia coli by DNA colony hybridization | |
Shirai et al. | Molecular epidemiologic evidence for association of thermostable direct hemolysin (TDH) and TDH-related hemolysin of Vibrio parahaemolyticus with gastroenteritis | |
Pollard et al. | Rapid and specific detection of verotoxin genes in Escherichia coli by the polymerase chain reaction | |
Lindenthal et al. | Identification of a glycoprotein produced by enterotoxigenic Escherichia coli | |
Vial et al. | Characterization of enteroadherent-aggregative Escherichia coli, a putative agent of diarrheal disease | |
Dozois et al. | Relationship between the Tsh autotransporter and pathogenicity of avian Escherichia coli and localization and analysis of the Tsh genetic region | |
Karch et al. | Evaluation of oligonucleotide probes for identification of Shiga-like-toxin-producing Escherichia coli | |
Yao et al. | CheY‐mediated modulation of Campylobacter jejuni virulence | |
Agin et al. | Identification of a family of intimins common to Escherichia coli causing attaching-effacing lesions in rabbits, humans, and swine | |
Zhu et al. | Virulence properties and attaching-effacing activity of Escherichia coli O45 from swine postweaning diarrhea | |
Lalioui et al. | Molecular cloning and characterization of the afa-7 and afa-8 gene clusters encoding afimbrial adhesins in Escherichia coli strains associated with diarrhea or septicemia in calves | |
McNally et al. | Differences in levels of secreted locus of enterocyte effacement proteins between human disease-associated and bovine Escherichia coli O157 | |
Sukupolvi et al. | TraT lipoprotein, a plasmid-specified mediator of interactions between gram-negative bacteria and their environment | |
Kennedy et al. | Attenuation and immunogenicity of Δcya Δcrp derivatives of Salmonella choleraesuis in pigs | |
Guidolin et al. | Genetics of Vibrio cholerae and its bacteriophages | |
Moseley et al. | Cloning of chromosomal DNA encoding the F41 adhesin of enterotoxigenic Escherichia coli and genetic homology between adhesins F41 and K88 | |
Monteiro‐Neto et al. | Characterization of an outer membrane protein associated with haemagglutination and adhesive properties of enteroaggregative Escherichia coli O111: H12 | |
JP2000511771A (en) | Pathogenic E. coli-related proteins | |
Alm et al. | Analysis of the role of flagella in the heat-labile Lior serotyping scheme of thermophilic Campylobacters by mutant allele exchange | |
US5703219A (en) | Nucleic acid encoding helicobacter pylori enolase | |
JP4189031B2 (en) | Live vaccine carrier strain useful for high level expression of variant O antigen from gram negative bacteria and its derivatives for use as live vaccine | |
Heuzenroeder et al. | Molecular cloning and expression in Escherichia coli K‐12 of the O101 rfb region from E. coli B41 (O101: K99/F41) and the genetic relationship to other O101 rfb loci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1989907053 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1989907053 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1989907053 Country of ref document: EP |